Email updates

Keep up to date with the latest news and content from Lipids in Health and Disease and BioMed Central.

Open Access Highly Accessed Research

Treatment of chronic hemodialysis patients with low-dose fenofibrate effectively reduces plasma lipids and affects plasma redox status

Agnieszka Makówka, Przemysław Dryja, Grażyna Chwatko, Edward Bald and Michał Nowicki*

Lipids in Health and Disease 2012, 11:47  doi:10.1186/1476-511X-11-47

PubMed Commons is an experimental system of commenting on PubMed abstracts, introduced in October 2013. Comments are displayed on the abstract page, but during the initial closed pilot, only registered users can read or post comments. Any researcher who is listed as an author of an article indexed by PubMed is entitled to participate in the pilot. If you would like to participate and need an invitation, please email, giving the PubMed ID of an article on which you are an author. For more information, see the PubMed Commons FAQ.

Fenofibrate Contraindications in United States

Jeffrey Minniti   (2015-01-09 12:57)  Martel Corporation email

In the US, severe renal disease is an absolute contraindication to the use of fenofibrate. This advisory is supported by the maker of Tricor and Trilipix (Abott), The National Kidney Foundation, and the National Lipid Association. The drug is significantly excreted by the kidneys, and is negligibly removed by hemodialysis. This study's duration was a mere 63 days. Toxic accumulation of fenofibrate has been documented in this patient population with more prolonged regimens. Many didn't become symptomatic until several months (or years) had passed. Neuromyopathy is not uncommon in this clinical setting. Gemfibrozil is the only fibrate that is OK'd for use in hemodialysis in the US. Even then, it requires regular monitoring of Creatine Kinase levels......and vigilance by the nephrologist. Idiopathic proximal weakness requires a thorough inquiry, with anuric patients being especially vulnerable in this scenario.

Competing interests



Renal Dosing

Jeffrey Minniti   (2013-10-21 21:04)  Minniti

In the US, fenofibrate is contraindicated in severe renal failure (including those on chronic dialysis). It has significant renal excretion, and is not removed by hemodialysis. Those with negligible creatinine clearances would be at risk for cumulative toxicity. Neuromyopathies (including rhabdomyolysis) have been documented in this patient population. Co-administered drugs such as colchicine can potentiate this effect.

Competing interests



Post a comment